bmn-673 and Brain-Neoplasms

Talazoparib is a poly (adenosine diphosphate-ribose) polymerase inhibitor approved for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative, locally advanced or metastatic breast cancer (LA/mBC), with approval based on the EMBRACA trial. To date, there are no published data on talazoparib use in the real-world United States (USA) setting.. Characteristics, treatment patterns, and clinical outcomes of real-world US patients with gBRCAm HER2-negative LA/mBC treated with talazoparib monotherapy were collected via retrospective chart review and summarized using descriptive statistics.. Among 84 eligible patients, 35.7% had hormone receptor-positive tumors and 64.3% had triple-negative LA/mBC (TNBC). At talazoparib initiation, 29.8% had ECOG PS of ≥2 and 19.0% had brain metastasis. Mutations in gBRCA1 or 2 were detected among 64.3% and 35.7% of patients, respectively. Talazoparib was given as 1st-line therapy in 14.3% of patients, 2nd-line in 40.5%, and 3rd- or 4th-line in 45.2%. Median time to talazoparib treatment failure was 8.5 months (95% CI, 8.0-9.7), median progression-free survival was 8.7 months (95% CI, 8.0-9.9), the median time from initiation to chemotherapy was 12.2 months (95% CI, 10.5-20.1), and the overall response rate was 63.1%. No differences in clinical outcomes were observed between patients with HR-positive/HER2-negative LA/mBC and patients with TNBC by using unadjusted statistical comparisons. Brain metastasis and ECOG PS ≥2 at talazoparib initiation were associated with treatment failure and progression or mortality.. Overall, talazoparib clinical outcomes in this real-world population are consistent with findings from EMBRACA.

Topics: Adult; Brain Neoplasms; Breast Neoplasms; Female; Humans; Retrospective Studies; Triple Negative Breast Neoplasms; United States

Exploration of novel strategies to extend the benefit of PARP inhibitors beyond. Selective sensitivity to the PARP inhibitor talazoparib was screened and validated in two sets [test set (

Topics: Animals; Brain Neoplasms; Cell Line, Tumor; DNA Damage; ErbB Receptors; Gene Amplification; Glioblastoma; Humans; Male; Mice; Mice, Nude; Oxidative Stress; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Spheroids, Cellular; Xenograft Model Antitumor Assays